Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951690 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Verastem.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT01951690: Completed Phase 2 study, sponsored by Verastem.
NCT01951690 is a Phase 2 study that has completed, run by Verastem. The registered enrollment target is 55 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951690, a Phase 2 study, has completed, sponsored by Verastem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). NSCLC with a KRAS mutation is required for study entry and subjects will be enrolled into 1 of 4 cohorts based on the status of their INK4a/Arf and p53 mutations. The purpose of this study is to demonstrate if VS-6063 (defactinib) improves PFS within each cohort. The safety and tolerability of VS-6063, tumor response rate, progression free survival and overall survival will also be assessed. The pharmacodynamic effects of VS-6063 (defactinib) will be examined in a tumor biopsy and a blood sample.
Interventions
- DRUG defactinib (VS-6063)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT01951690 record still lists
NCT01951690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which defactinib (VS-6063) is the first listed.
NCT01951690 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01951690 about?
NCT01951690 is a clinical study titled "Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer". This is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). NSCLC with a KRAS mutation is required for study entry and subjects will be enrolled into 1 of 4 cohorts based...
What is the current status of trial NCT01951690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2013-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01951690?
The interventions under investigation include: defactinib (VS-6063) (DRUG).
Who is sponsoring clinical trial NCT01951690?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01951690's enrollment target sits among peer trials
55 1153rd of 2000 higher than 841 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia